Blockade of a key cytokine for MDSCs function, IL10, restores immunosurveillance and improves survivalPeripheral blood ARG/IDO/IL10+ MDSCs are especially abundant in patients with advanced ovarian cancer and their depletion is a good prognostic factorBRCA-mutated patients have less MDSCs and more T CD*+ effectors than patients with wild BRCA copy in early stage HGSOC, what could explain partly the survival benefit in this group of patients. The gene discussed is IL10; the disease is ovarian cancer.